CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score -0.05: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
312.59MUSDvs all stocks (USD)
Revenue (TTM)
215.72MUSDvs all stocks (USD)
Profit Margin
-127.41%vs Biotechnology peers
Beta
0.6450xvs all stocks
52-Week Change
5.30%vs all stocks
Market Capitalization
312.59MUSDvs all stocks (USD)
Enterprise Value
158.14MUSDvs all stocks (USD)
Forward P/E
25.25xvs Biotechnology peers
Price to Sales (TTM)
1.42xvs Biotechnology peers
Price to Book (MRQ)
1.08xvs Biotechnology peers
Enterprise to Revenue
0.7330xvs Biotechnology peers
Enterprise to EBITDA
-0.8930xvs Biotechnology peers
Gross Margin
92.95%vs Biotechnology peers
Profit Margin
-127.41%vs Biotechnology peers
Operating Margin
-126.28%vs Biotechnology peers
Return on Assets (TTM)
-22.38%vs Biotechnology peers
Return on Equity (TTM)
-77.81%vs Biotechnology peers
Revenue (TTM)
215.72MUSDvs all stocks (USD)
Revenue per Share (TTM)
3.63USDUpdated Sep 28, 2026Quarterly Revenue Growth
-3.90%vs Biotechnology peers
Gross Profit (TTM)
202.22MUSDvs all stocks (USD)
EBITDA (TTM)
-177.05MUSDvs all stocks (USD)
Net Income (TTM)
-274.85MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-3.92%vs Biotechnology peers
Operating Cash Flow (TTM)
-142.33MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-86.72MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
216.10MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
13.04MUSDFY2025 · Dec 31, 2025Gross Profit
203.06MUSDFY2025 · Dec 31, 2025Operating Income
-151.17MUSDvs all stocks (USD)
Pre-tax Income
-138.65MUSDFY2025 · Dec 31, 2025Income Tax Expense
81.83MUSDFY2025 · Dec 31, 2025Net Income
-220.47MUSDFY2025 · Dec 31, 2025EBIT
-151.17MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-139.25MUSDFY2025 · Dec 31, 2025Research & Development
109.27MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
237.95MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.74USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.74USDFY2025 · Dec 31, 2025Basic Shares Outstanding
58.93MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
58.93MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-220.47MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-95.32MUSDFY2025 · Dec 31, 2025Free Cash Flow
-96.32MUSDDerived from operating cash flow minus capital expenditure. This filing charges 11.92M of depreciation against 998K of capital expenditure, and its own free-cash-flow line reads -110.44M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
85.32MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-220.47MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
11.92MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
81.44MUSDFY2025 · Dec 31, 2025Stock-based Compensation
9.47MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.94MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-7.46MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
15.82MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
12.02MUSDFY2025 · Dec 31, 2025Capital Expenditures
-998.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-112.38MUSDFY2025 · Dec 31, 2025Sale of Investments
208.24MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
94.86MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.99MUSDFY2025 · Dec 31, 2025Other Financing Charges
-915.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-2.91MUSDFY2025 · Dec 31, 2025Shares Outstanding
60.45MSharesUpdated Sep 28, 2026Float Shares
47.66MSharesUpdated Sep 28, 2026Shares Short
8.50MSharesUpdated Sep 28, 2026Short Ratio
11.28daysvs all stocks
Short % of Shares Outstanding
14.75%vs all stocks
% Held by Insiders
6.61%vs all stocks
% Held by Institutions
86.45%vs all stocks
Total Cash (MRQ)
170.03MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.81USDUpdated Sep 28, 2026Total Debt (MRQ)
22.83MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1037xvs Biotechnology peers
Current Ratio (MRQ)
1.61xvs Biotechnology peers
Book Value per Share (MRQ)
4.67USDUpdated Sep 28, 2026Total Assets
488.95MUSDvs all stocks (USD)
Total Current Assets
347.26MUSDFY2025 · Dec 31, 2025Total Liabilities
161.76MUSDFY2025 · Dec 31, 2025Total Non-current Assets
141.69MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
16.60MUSDFY2025 · Dec 31, 2025Total Current Liabilities
145.16MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
84.85MUSDFY2025 · Dec 31, 2025Other Short-term Investments
179.00MUSDFY2025 · Dec 31, 2025Accounts Receivable
54.58MUSDFY2025 · Dec 31, 2025Inventory
1.85MUSDFY2025 · Dec 31, 2025Accounts Payable
4.94MUSDFY2025 · Dec 31, 2025Short-term Debt
5.55MUSDFY2025 · Dec 31, 2025Long-term Debt
7.07MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
9.53MUSDFY2025 · Dec 31, 2025Common Stock (Book)
59.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-394.77MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
327.19MUSDvs all stocks (USD)
52-Week Low
4.27USDUpdated Sep 28, 202652-Week High
9.94USDUpdated Sep 28, 202652-Week Change
5.30%vs all stocks
Beta
0.6450xvs all stocks
50-Day MA
5.23USDUpdated Sep 28, 2026200-Day MA
6.57USDUpdated Sep 28, 2026Avg 10-Day Volume
841.98KSharesUpdated Sep 28, 2026Avg 30-Day Volume
787.18KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-4.64USDUpdated Sep 28, 2026Other Income / Expense
12.52MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.93Profit Margin: -1.27
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 1.61Altman Z-Score: -0.05
Financial Health
Altman Z-Score -0.05: distress zoneCritical
Altman Z-Score: -0.05
High earnings qualityNotable
Earnings Quality Score: 0.71
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Won Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guiyang Xintian Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
CytoDyn Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Aprilbio Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Medy-Tox Inc.
Tier 1ProductionApproval-Gated PipelineRule
Animalcare Group Plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
Abeona Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Enwei Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
BridgeBio Oncology Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jilin Province Xidian Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule